Kezar Life Sciences
4000 Shoreline Court, Suite 300
South San Francisco, CA 94080
Biotech and Pharmaceutical
Drug Discovery and Development
Kezar Life Sciences was founded in 2015 by Christopher Kirk, Ph.D., John Fowler, and Jack Taunton, Ph.D. to discover and develop innovative new therapies targeting protein homeostasis. Kezar’s first drug candidate, KZR-616, a selective inhibitor of the immunoproteasome, entered clinical trials in 2016.